Kodiak Sciences Inc
KODDrugs in Pipeline
4
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Dec 31, 2026
14wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How KOD's past catalysts played out
KSI-101
Macular Edema Secondary to Inflammation
KSI-301
Macular Edema
Tarcocimab
Diabetic Retinopathy
Tarcocimab tedromer
Wet Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KSI-101 | Phase 3 | Macular Edema Secondary to Inflammation | - | - |
KSI-301 | Phase 3 | Macular Edema | - | - |
Tarcocimab | Phase 3 | Diabetic Retinopathy | - | - |
Tarcocimab tedromer | Phase 3 | Wet Age-related Macular Degeneration | - | - |
Macular Edema Secondary to Inflammation
1 drug in this indication
Diabetic Retinopathy
1 drug in this indication
Macular Edema
1 drug in this indication
Wet Age-related Macular Degeneration
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kodiak Sciences Inc's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Kodiak Sciences Inc's (KOD) pipeline across Phase 3. Its lead program is KSI-101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kodiak Sciences Inc's next FDA catalyst?→
Kodiak Sciences Inc's (KOD) next tracked catalyst is a Phase 3 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KOD biotech catalysts?→
Add KOD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kodiak Sciences Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.